IMAAGEN研究:阿比特龙联合泼尼松对高危非转移性去势抵抗性前列腺癌PSA及影像学进展的影响
IMAAGEN研究评估阿比特龙醋酸酯(1000 mg)联合泼尼松(5 mg)治疗高危非转移性去势抵抗性前列腺癌患者,主要终点为第1至6周期内PSA下降≥50%的比例。131例患者中86.9%达到PSA下降≥50%,59.8%达到≥90%,中位PSA进展时间28.7个月。
要点
- 高危非转移性CRPC患者中,阿比特龙联合泼尼松使86.9%患者PSA下降≥50%。
- 中位PSA进展时间28.7个月,影像学进展时间未达到。
- 基线睾酮≥12.5 ng/dl及第3周期PSA下降≥90%与更长的进展时间相关。
核心结论
- 在高危非转移性去势抵抗性前列腺癌患者中,阿比特龙联合泼尼松(5 mg)治疗可使86.9%患者PSA下降≥50%,次要终点结果令人鼓舞。
研究设计与样本
- 单臂研究,纳入131例高危非转移性去势抵抗性前列腺癌患者,接受阿比特龙醋酸酯1000 mg联合泼尼松5 mg每日治疗,28天为一周期。
- 高危定义:PSA≥10 ng/ml或PSA倍增时间≤10个月。
主要发现
- 131例中44例(34%)仍在治疗,中位随访40.0个月,中位年龄72岁(范围48-90)。
- PSA显著下降(p<0.0001),86.9%患者PSA下降≥50%,59.8%下降≥90%。
- 中位PSA进展时间28.7个月(95%CI 21.2-38.2)。
- 影像学进展时间未达到,敏感性分析中15例估计为41.4个月(95%CI 27.6-不可估计)。
- 基线睾酮≥12.5 ng/dl及第3周期PSA下降≥90%与更长的PSA进展时间和影像学进展时间相关。
关键数值与推荐
- 主要终点:第1至6周期内PSA下降≥50%的比例为86.9%。
- PSA下降≥90%的比例为59.8%。
- 中位PSA进展时间28.7个月(95%CI 21.2-38.2)。
- 影像学进展时间敏感性分析估计41.4个月(95%CI 27.6-不可估计)。
- 不良事件发生率96.2%,≥3级不良事件61.1%,严重不良事件43.5%。
临床怎么用
- 对于高危非转移性去势抵抗性前列腺癌患者,阿比特龙联合低剂量泼尼松(5 mg)可显著降低PSA并延缓进展。
- 基线睾酮≥12.5 ng/dl及第3周期PSA下降≥90%可作为疗效预测指标。
局限性
- 单臂研究,无对照组。
- 影像学进展时间未达到,敏感性分析仅基于15例患者。
- 随访期间44例(34%)仍在治疗,数据尚不成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the use of abiraterone acetate (1,000 mg) plus prednisone (5 mg) in patients with high risk, nonmetastatic, castration resistant prostate cancer. MATERIALS AND METHODS: Patients considered at high risk for progression to metastatic disease (prostate specific antigen 10 ng/ml or greater, or prostate specific antigen doubling time 10 months or less) received abiraterone acetate plus prednisone daily in 28-day cycles. The primary study end point was the proportion of patients in whom a 50% or greater prostate specific antigen reduction was achieved during cycles 1 to 6. Secondary end points included time to prostate specific antigen progression, time to radiographic evidence of disease progression and safety. RESULTS: Of the 131 enrolled patients 44 (34%) remained on treatment with a median followup of 40.0 months. Median age was 72 years (range 48 to 90). Of the patients 82.4% were white and 14.5% were black. Median screening prostate specific antigen was 11.9 ng/dl and median prostate specific antigen doubling time was 3.4 months. Prostate specific antigen was significantly reduced (p <0.0001) with a 50% or greater prostate specific antigen reduction in 86.9% of cases and a 90% or greater reduction in 59.8%. Median time to prostate specific antigen progression was 28.7 months (95% CI 21.2-38.2). Median time to radiographic evidence of disease progression was not reached but on sensitivity analysis in 15 patients it was estimated to be 41.4 months (95% CI 27.6-not estimable). Baseline testosterone 12.5 ng/dl or greater and a 90% or greater prostate specific antigen reduction at cycle 3 were associated with longer time to prostate specific antigen progression and radiographic evidence of disease progression. Outcomes in black patients were similar to those in other patients. Adverse events, grade 3 or greater adverse events and serious adverse events were reported in 96.2%, 61.1% and 43.5% of patients, respectively. CONCLUSIONS: In patients with high risk, nonmetastatic, castration resistant prostate cancer treatment with abiraterone acetate plus prednisone demonstrated a significant 50% or greater prostate specific antigen reduction with encouraging results for the secondary end points, including the safety of 5 mg prednisone.
引用
- Ryan CJ, Crawford ED, Shore ND, et al. The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. J Urol. 2018. PMID: 29630978. doi:10.1016/j.juro.2018.03.125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。